These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9441946)

  • 1. The physiological function of drug-transporting P-glycoproteins.
    Schinkel AH
    Semin Cancer Biol; 1997 Jun; 8(3):161-70. PubMed ID: 9441946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological insights from P-glycoprotein knockout mice.
    Schinkel AH
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):9-13. PubMed ID: 9476142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in P-glycoprotein research.
    Ueda K; Yoshida A; Amachi T
    Anticancer Drug Des; 1999 Apr; 14(2):115-21. PubMed ID: 10405638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of P-glycoprotein at blood-tissue barriers.
    Fromm MF
    Trends Pharmacol Sci; 2004 Aug; 25(8):423-9. PubMed ID: 15276711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does inhibition of P-glycoprotein lead to drug-drug interactions?
    Balayssac D; Authier N; Cayre A; Coudore F
    Toxicol Lett; 2005 Apr; 156(3):319-29. PubMed ID: 15763631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
    Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
    J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier.
    Bauer B; Hartz AM; Fricker G; Miller DS
    Mol Pharmacol; 2004 Sep; 66(3):413-9. PubMed ID: 15322232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
    Smit JW; Schinkel AH; Müller M; Weert B; Meijer DK
    Hepatology; 1998 Apr; 27(4):1056-63. PubMed ID: 9537446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein: from genomics to mechanism.
    Ambudkar SV; Kimchi-Sarfaty C; Sauna ZE; Gottesman MM
    Oncogene; 2003 Oct; 22(47):7468-85. PubMed ID: 14576852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cmdr1, a chicken P-glycoprotein, confers multidrug resistance and interacts with estradiol.
    Edelmann HM; Duchek P; Rosenthal FE; Föger N; Glackin C; Kane SE; Kuchler K
    Biol Chem; 1999 Feb; 380(2):231-41. PubMed ID: 10195430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein activity and biological response.
    Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
    Grauer MT; Uhr M
    J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
    Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
    Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
    Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
    Tahara H; Kusuhara H; Fuse E; Sugiyama Y
    Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confocal imaging of xenobiotic transport across the blood-brain barrier.
    Miller DS
    J Exp Zool A Comp Exp Biol; 2003 Nov; 300(1):84-90. PubMed ID: 14598390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME; Podila L; Ely D; Almeida I
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
    Smit JW; Schinkel AH; Weert B; Meijer DK
    Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs.
    Smit JW; Weert B; Schinkel AH; Meijer DK
    J Pharmacol Exp Ther; 1998 Jul; 286(1):321-7. PubMed ID: 9655875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney.
    Ernest S; Bello-Reuss E
    Kidney Int Suppl; 1998 Apr; 65():S11-7. PubMed ID: 9551426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.